A Phase II Study of AZD2171 (Cediranib) in the Treatment of Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Leukemia and Lymphoma - United Kingdom
doi 10.3109/10428194.2014.977886
Full Text
Open PDFAbstract
Available in full text
Date
November 19, 2014
Authors
Publisher
Informa UK Limited